ClinicalTrials.gg
RecruitingNCT07719946Updated Jul 22, 2026

To Study Lower Dose of Cyclophosphamide After Stem Cell Transplant for Blood Cancers

A Phase 2 interventional study of Cyclophosphamide in Haploidentical Hematopoietic Stem Cell Transplant and Hematological Malignancies, sponsored by Tata Memorial Centre. Recruiting at 2 sites in India. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-07-22.

Sponsored by Tata Memorial Centre · Phase 2, Interventional, and Prevention

How we know

From the registry’s dates

  • Registered 1 year 3 months after the study started (first participant enrolled Mar 2025, registered Jul 2026).
  • Started Mar 2025; still recruiting 1 year 7 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
20
Allocation
Not applicable
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 53 studies testing cyclophosphamide in Hematologic Neoplasms — 18 open to participants now, 20 under way, 1 of them phase 3. Cyclophosphamide · Hematologic Neoplasms.

Planned enrollment
38th of 52
20 · median 44
Started
2025
the only one that year
Phase 2
30 of 53
7 open now
Primary completion
2028-11
later than 11 of 19 live
Registered
52nd of 53
by date

Among the 53 studies testing cyclophosphamide in Hematologic Neoplasms, this one is the 38th largest by planned enrollment of the 52 interventional ones that give a count, is the only one that started in 2025, is one of 30 in phase 2, reaches primary completion later than 11 of the 19 other live ones, and was the 52nd registered.

Hematologic Neoplasms

1,449 studies on the registry are indexed under Hematologic Neoplasms; 422 are open to participants now.

Browse Hematologic Neoplasms studies →

Open to participants now

18 of the 53 studies testing cyclophosphamide in Hematologic Neoplasms are open now, in 6 countries. Recruiting first, the newest first:

12 more — sign in →

By country, each count listing its studies:

All 18 open studies →

About cyclophosphamide

Cyclophosphamide: first FDA approval 1959 (CYTOXAN). What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 313 Hematologic Neoplasms studies recruiting now, 209 (67%) set no upper age limit and 78 (25%) stop at 75 or younger; 81 take children under 18; 34 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 53 studies testing cyclophosphamide in Hematologic Neoplasms, or all of them as a file.
02

Study summary

Cyclophosphamide is the name of a medicine given to prevent graft-versus-host-disease (GVHD) after half-matched transplant. This medicine is given on the 3rd and 4th day after stem cell transplant. The standard dose of this medicine is 50 mg per kg of the patient's weight given on the 3rd and the 4th day. However, using this medicine at this dose of 50 mg / kg for 2 days is associated with certain problems such as susceptibility to infections and delay in the recovery of the immune system after stem cell transplant. Therefore, several research groups across the world have tried to reduce the dose of cyclophosphamide that is used. These groups have tried reducing the dose from 50 mg per kg to 25-40 mg per kg. These studies have shown that the reduced dose cyclophosphamide is equally effective in preventing GVHD. However, these studies are carried out on small numbers of patients and further studies are essential to confirm whether reduced dose of cyclophosphamide is equally effective. In this study, we will use cyclophosphamide at a lower dose (25 mg/kg x 2 days) and see if the lower dose results in equal efficacy but lesser toxicities This is a single-arm study. All participants will receive the same treatment; there is no comparison group.

Participants will:

Adults (age ≥18) undergoing haploidentical stem cell transplant for blood cancers Receive low-dose cyclophosphamide (25 mg/kg/day) on Day 3 and Day 4 after transplant Also receive standard GVHD preventive medicines (calcineurin inhibitor and mycophenolate) Undergo regular blood tests, immune system monitoring, and GVHD assessments Have immune cell and cytokine profiles analyzed through blood samples

Read the detailed description

Background: Allogeneic Hematopoietic stem cell transplant (HSCT) is often the only curative treatment option for patients with end stage hematological malignancies. Haploidentical HSCT is increasingly being adopted worldwide due to ease of access to donors. Post transplant cyclophosphamide (PTCy) has revolutionized the way the world does T cell replete haploidentical transplant. However, the success of PTCy comes at the cost of delayed engraftment and increased organ toxicities. Reduced dose of PTCy may be equally effective in GvHD prevention and translate into better engraftment kinetics and immune reconstitution Objectives: To evaluate the GvHD prophylactic effect of reduced dose PTCy in combination with Calcineurin inhibitors and MMF for haploidentical HSCT.

Novelty: The proposed study is a prospective phase 2 trial of reduced dose PTCy as GvHD prophylaxis in haplo HSCT. By demonstration of equal GvHD prevention efficacy of reduced dose PTCy this study would provide the base for phase 3 randomised trial and provide practice changing answers.

Study treatment:

Post-transplant Immunosuppression:

● GvHD prophylaxis regimen will consist of two doses of cyclophosphamide on D+3 and D+4 at 25mg/kg/day (that is half of the usual standard dose) with calcineurin inhibitor and mycophenolate mofetil / mycophenolate sodium. Mesna will be given with cyclophosphamide (this is standard of care). The use of calcineurin inhibitors and mycophenolate mofetil / mycophenolate sodium will be as per standard practice.

Administration of study treatments

  • Hydration and MESNA
  • Adequate intravenous hydration with normal saline will be started at least 4 hours prior to cyclophosphamide, and will be continued till 24 hours post completion of 2nd dose of cyclophosphamide as per standard institutional practice.
  • Mesna will be administered as a continuous infusion starting from Day+3 till 24 hours after the second dose of PTCy.
  • Cyclophosphamide
  • Cyclophosphamide would be administered on D+3 and D+4 [first dose starting between 60 - 72 hrs after stem cell infusion] at a dose of 25 mg/kg/day intravenously as an intravenous infusion over 2 hrs. The timing of cyclophosphamide and the infusion time of 2 hours are standard of care. The actual administered dose can be rounded off to the nearest 100 mg (Eg if the dose is 1760 mg, the actual administered dose can be 1800 mg)
  • Study treatment: Cyclophosphamide.
  • Dosage: 25 mg/kg/day.
  • Dosage schedule: Day+3 and Day+4 of transplant.
  • Route/Mode of administration: Intravenous infusion over 2 hrs with Mesna. Assessment Plan (All the below assessments are according to standard institutional protocols and policies. These are not specific for this study)
  • The day of neutrophil engraftment and platelet engraftment will be captured.
  • Donor chimerism will be assessed by FISH[XX/XY] in case of sex mismatched transplants and with VNTR chimerism studies on day +14, day +28 and monthly thereafter for 1 year. Additional chimerism studies can be done if clinically indicated
  • aGvHD grading will be determined by the investigator as per Modified Glucksberg criteria on a weekly basis for the first 100 days and every 28 days thereafter, as well as at scheduled study visits on Days 100, 180, and 365 and at the end of treatment. Additional assessments will be done if clinically indicated. Assessment of acute GVHD is primary clinical with additional investigations if deemed necessary. These time points are same as that followed in clinical practice and no extra study-specific assessments are needed.
  • Chronic GVHD will be diagnosed and graded based on NIH and Seattle consensus criteria. The time to onset of limited and extensive chronic GVHD will also be recorded.
  • Adverse events will be assessed according to National Cancer Institute Common Terminology Criteria for Adverse Events v 5.0 from the time of cyclophosphamide till day +30.
  • Immune Reconstitution will be assessed at Day+30, Day+60, Day+90, Day+180 and Day +365. This assessment will be done by lymphocyte subset analysis and is being done for all transplant patients at the mentioned time point at our institute. These are not study specific but the same as what is followed in standard institutional practice.
  • Cytokine analysis will be done at baseline, Day+1, Day+3, Day +5 and +7. These too are done as a standard practice for all haplo-identical transplants, and hence are not specific to the study.
  • The days above assessments (not being study specific, but as usual in standard practice), can be adjusted according to patient's OPD follow up days to coincide with their routine blood collections. It may be noted that all BMT patients are followed up at least twice a week till 100 days (3 months) post BMT.

Characterization of immune cell profile using 16-color flow cytometry Peripheral blood samples will be studied for various immune cell subsets using the bulk-lyse and stain method. Antibody staining will be performed using a 16-color antibody panel and cells will be acquired on a BD LSR Fortessa flow cytometer. A minimum of 100000 cells will be studied in each panel. This panel will provide more than 100 immune cell subsets. Flow cytometry data will be analyzed using Kaluza software version 2.0 and tSNE software. The different immune cell subsets will be categorized. Absolute counts of these subsets will be calculated in PB samples with WBC counts using the dual-platform method.

Cytokine profile analysis Cytokine profile analysis for cytokines such as IL-1β, IL-6, IL-8, IL-10, IL-12p70, IFN-γ, TNF-α, IP-10, GM-CSF, etc., will be performed using the patient's peripheral blood plasma samples (within 4 h of collection) using a bead-based immunoassay (CBA, BD Biosciences, and BioLegend's LEGENDplex™) according to the manufacturer's instructions. In brief, 50 µL of prepared capture bead mixture will be mixed with 50 µL of the diluted sample and incubated at room temperature for 1.5 h. Then, 50 µL of the detection reagent will be added to this mixture and incubated for 1.5 h. The detection reagent is a mixture of analyte-specific antibodies conjugated to phycoerythrin. Incubation of the samples with capture beads and then the detection reagent leads to the formation of a "sandwich complex" of the three. These complexes will be acquired on LSRFortessa (BD Biosciences), and data will be analyzed using FCAP Array software (BD Biosciences) and LEGENDplex version 8.0 software (BioLegend).

Sample size Based on our historical data, the expected incidence of grades 3 and 4 aGvHD is estimated to be 30%. The study will enroll a total of 20 patients using a Simon 2-stage design. If in the initial 10 patients enrolled, 4 or more develop acute grade III or IV GVHD, then we will stop the study. If 3 or less patients develop acute grade III or IV GVHD, then we will complete the enrollment of the planned 20 patients. We expect to complete the enrollment in 4 years.

Statistical Analysis All continuous data will be expressed as median and IQR. Categorical data will be expressed as frequency and percentage. The incidence of acute and chronic GvHD, relapse, and NRM will be estimated based on cumulative incidence methods accounting for competing event (TRM or death due to any cause). Overall Survival and Relapse Free Survival probabilities will be estimated by the Kaplan-Meier method.

The platelet and neutrophil engraftment will be expressed using median and IQR. Statistical analysis will be performed by appropriate statistical tests using IBM SPSS v25 (statistical package for social sciences) software.

Study Timeline and Oversight

Duration: 4 years (estimated)

Site: Advanced Centre for Treatment, Research and Education in Cancer (ACTREC)

Sample size: 20 patients

Provision of ancillary care for unrelated illness during the duration of the study:

Allogeneic stem cell transplant is associated with development of several kinds of post-transplant complications. All such complications will be managed as per standard of care by the transplant team and as mentioned previously, the patient will bear the cost of such management.

Plan for Missing Data Predefined rules will be applied to classify missing, uninterpretable, or inconsistent data.

Privacy, confidentiality and anticipated consequences of breach of confidentiality:

All the study data will remain in a password protected document which will be accessible only to the study investigators and the regulatory authorities. In any presentation originating from the study or any publication, no reference will be made to individual patients. Any data presentation will always be de-identified.

The fact that the patient has undergone an allogeneic HSCT would be available / made known to several clinicians and other medical / paramedical staff who would be involved in patient care. Since there are no additional study specific assessments or follow ups, any breach of information about your trial participation is unlikely to have any consequences.

Compensation and reimbursement:

Transplant related complications (which may lead to fatal outcomes) are inherent complications of half-matched transplants. These could occur irrespective of trial participation. Therefore, the study does not have a provision for compensation (since these complications can occur irrespective of study participation). Also, because of the same reason, there is no reimbursement and the cost of management of complications will be borne by the patient.

All trial-related data will be collected in accordance with institutional standard operating procedures (SOPs).

03

Conditions studied

  • Haploidentical Hematopoietic Stem Cell Transplant
  • Hematological Malignancies

Keywords

  • Low dose cyclosphosphamide
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Eligibility criteria

Inclusion Criteria: -

  • Patients age ≥ 18 years
  • performance score of 0 or 1

Exclusion Criteria: -

  • Presence of an active uncontrolled infection defined as hemodynamic instability attributable to sepsis or new symptoms, worsening physical signs, or radiographic findings attributable to infection.
  • Any medical or psychiatric illness which precludes the participant from giving .
  • Organ function criteria: Serious organ dysfunctions:
  • Serious cardiac dysfunction: \< 45%; no uncontrolled arrhythmias or symptomatic cardiac disease.
  • Serious pulmonary organ dysfunction: Symptomatic pulmonary disease; (FEV1), forced vital capacity (FVC), diffusion capacity of the lung for carbon monoxide (DLCO) =\< 50% of predicted (corrected for ).
  • Serious renal dysfunction: Measured serum =\< 60 mL/min.
  • Serious Hepatic dysfunction: Total serum more than twice upper normal limit or (ALT) or aspartate aminotransferase (AST) more than 3-fold higher than laboratory upper normal limits.
Terms in these criteria, in plain language(8)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

LVEF (left ventricular ejection fraction)

The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.

FEV1

From a breathing test (spirometry): how much air you can blow out in the first second. Often given as a percentage of what is expected for your age, height and sex.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

Creatinine clearance (CrCl)

How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

05

Study design

Phase
Phase 2
Primary purpose
Prevention
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
20 participants (estimated)

Study arms

  • Experimental
    Low dose cyclosphosphamide

    Single Arm study and cyclophosphamide at a lower dose (25 mg/kg x 2 days)

    Drug: Cyclophosphamide

Interventions

  • Post-transplant Immunosuppression: ● GvHD prophylaxis regimen will consist of two doses of cyclophosphamide on D+3 and D+4 at 25mg/kg/day (that is half of the usual standard dose) with calcineurin inhibitor and mycophenolate mofetil / mycophenolate sodium. Mesna will be given with cyclophosphamide (this is standard of care). The use of calcineurin inhibitors and mycophenolate mofetil / mycophenolate sodium will be as per standard practice. Administration of study treatments * Hydration and MESNA * Adequate intravenous hydration with normal saline will be started at least 4 hours prior to cyclophosphamide, and will be continued till 24 hours post completion of 2nd dose of cyclophosphamide as per standard institutional practice. * Mesna will be administered as a continuous infusion starting from Day+3 till 24 hours after the second dose of PTCy. * Cyclophosphamide * Cyclophosphamide would be administered on D+3 and D+4 \[first dose starting between 60 - 72 hrs after stem cell infusion\]

06

What researchers measure

Primary outcomes

  1. Severe (Grade 3-4) aGvHD

    To evaluate the cumulative incidence of severe (Grade 3-4) aGvHD

    Time frame: at day 100 Post Transplant

Secondary outcomes

  1. Cumulative incidence of clinically significant (Grade 2-4) acute graft-versus-host disease (aGvHD)

    To evaluate the cumulative incidence of clinically significant (Grade 2-4) acute GvHD following transplantation.

    Time frame: Day 100 and Day 180 post-transplant

  2. Cumulative incidence of severe (Grade 3-4) acute graft-versus-host disease (aGvHD)

    To evaluate the cumulative incidence of severe (Grade 3-4) acute GvHD following transplantation.

    Time frame: Day 180 post-transplant

  3. Graft-versus-host disease and relapse-free survival (GRFS)

    To evaluate graft-versus-host disease and relapse-free survival (GRFS). GRFS events include grade III or IV acute GvHD, extensive chronic GvHD, disease relapse, or death.

    Time frame: 1 year post-transplant

  4. Incidence of chronic graft-versus-host disease (cGvHD

    To evaluate the cumulative incidence of chronic GvHD following transplantation.

    Time frame: 1 year post-transplant

  5. Neutrophil engraftment

    To evaluate the time to neutrophil engraftment following transplantation, defined according to the study protocol.

    Time frame: Up to Day 100 post-transplant

  6. Platelet engraftment

    To evaluate the time to platelet engraftment following transplantation, defined according to the study protocol.

    Time frame: Up to Day 100 post-transplant

  7. Regimen-related toxicity

    To evaluate the incidence and severity of regimen-related toxicity following transplantation.

    Time frame: Up to Day 100 post-transplant

  8. Transplant-related mortality (TRM)

    To evaluate the cumulative incidence of transplant-related mortality following transplantation.

    Time frame: 1 year post-transplant

  9. Overall survival (OS)

    To evaluate overall survival following transplantation.

    Time frame: 1 year post-transplant

07

Study locations

1 of 2 sites recruiting
  • Advanced Centre for Treatment, Research and Education in Cancer
    Navi Mumbai, Maharashtra 410210, India
    Not yet recruiting
    • Sachin Punatar, MBBS DM MD Medical Oncology · Contactdrsachin_punatar@yahoo.in · 09833445041
    • Akanksha Chichra, FNB,DNB Pediatric Oncology · Contactakanksha7@hotmail.com
    • Dr.Sachin Punatar, MBBS DM MD Medical Oncology · Principal investigator
    • Lingaraj Nayak, MBBS DM MD Medical Oncology · Sub investigator
  • Advanced Centre for Treatment, Research and Education in Cancer
    Navi Mumbai, Maharashtra 410210, India
    Recruiting
    • Sachin Punatar, MBBS DM MD Medical Oncology · Contactdrsachin_punatar@yahoo.in · 09833445041
    • Akanksha Chichra, FNB,DNB Pediatric Oncology · Contactakanksha7@hotmail.com · 9004920555
    • Sachin Punatar, MBBS DM MD Medical Oncology · Principal investigator
08

References and documents

Publications

  • Sugita J, Kamimura T, Ishikawa T, Ota S, Eto T, Kuroha T, Miyazaki Y, Kumagai H, Matsuo K, Akashi K, Taniguchi S, Harada M, Teshima T. Reduced dose of posttransplant cyclophosphamide in HLA-haploidentical peripheral blood stem cell transplantation. Bone Marrow Transplant. 2021 Mar;56(3):596-604. doi: 10.1038/s41409-020-01065-0. Epub 2020 Sep 24. PubMed 32973350 ↗
  • Nakamae H, Koh H, Katayama T, Nishimoto M, Hayashi Y, Nakashima Y, Nakane T, Nakamae M, Hirose A, Hino M. HLA haploidentical peripheral blood stem cell transplantation using reduced dose of posttransplantation cyclophosphamide for poor-prognosis or refractory leukemia and myelodysplastic syndrome. Exp Hematol. 2015 Nov;43(11):921-929.e1. doi: 10.1016/j.exphem.2015.07.006. Epub 2015 Aug 15. PubMed 26284307 ↗
  • Meredith J. McAdams, Dimana Dimitrova, Jennifer L. Sadler, Seth M. Steinberg, Jennifer Cuellar-Rodriguez, Thomas E. Hughes, Nuri Cha, Ellen B. Carroll, Stephanie N. Hicks, Amy Chai, Scott Napier, Anita Stokes, Richard Kwan, Jennifer Sponaugle, Mustafa Hyder, Ronald E. Gress, Jennifer A. Kanakry, Chris G. Kanakry. Phase I Study De-Intensifying Exposure of Post Transplantation Cyclophosphamide (PTCy) after HLA Haploidentical Hematopoietic Cell Transplantation (HCT) for Hematologic Malignancies. Transplant Cell Ther 27 3S (2021) S1-S488.
  • Wachsmuth LP, Patterson MT, Eckhaus MA, Venzon DJ, Kanakry CG. Optimized Timing of Post-Transplantation Cyclophosphamide in MHC-Haploidentical Murine Hematopoietic Cell Transplantation. Biol Blood Marrow Transplant. 2020 Feb;26(2):230-241. doi: 10.1016/j.bbmt.2019.09.030. Epub 2019 Oct 2. PubMed 31586477 ↗
  • Goldsmith SR, Abid MB, Auletta JJ, Bashey A, Beitinjaneh A, Castillo P, Chemaly RF, Chen M, Ciurea S, Dandoy CE, Diaz MA, Fuchs E, Ganguly S, Kanakry CG, Kanakry JA, Kim S, Komanduri KV, Krem MM, Lazarus HM, Liu H, Ljungman P, Masiarz R, Mulroney C, Nathan S, Nishihori T, Page KM, Perales MA, Taplitz R, Romee R, Riches M. Posttransplant cyclophosphamide is associated with increased cytomegalovirus infection: a CIBMTR analysis. Blood. 2021 Jun 10;137(23):3291-3305. doi: 10.1182/blood.2020009362. PubMed 33657221 ↗
  • Dulery R, Mohty R, Labopin M, Sestili S, Malard F, Brissot E, Battipaglia G, Mediavilla C, Banet A, Van de Wyngaert Z, Paviglianiti A, Belhocine R, Isnard F, Lapusan S, Adaeva R, Vekhoff A, Ledraa T, Legrand O, Cohen A, Bonnin A, Ederhy S, Mohty M. Early Cardiac Toxicity Associated With Post-Transplant Cyclophosphamide in Allogeneic Stem Cell Transplantation. JACC CardioOncol. 2021 Jun 15;3(2):250-259. doi: 10.1016/j.jaccao.2021.02.011. eCollection 2021 Jun. PubMed 34396331 ↗
  • Luznik L, O'Donnell PV, Symons HJ, Chen AR, Leffell MS, Zahurak M, Gooley TA, Piantadosi S, Kaup M, Ambinder RF, Huff CA, Matsui W, Bolanos-Meade J, Borrello I, Powell JD, Harrington E, Warnock S, Flowers M, Brodsky RA, Sandmaier BM, Storb RF, Jones RJ, Fuchs EJ. HLA-haploidentical bone marrow transplantation for hematologic malignancies using nonmyeloablative conditioning and high-dose, posttransplantation cyclophosphamide. Biol Blood Marrow Transplant. 2008 Jun;14(6):641-50. doi: 10.1016/j.bbmt.2008.03.005. PubMed 18489989 ↗
  • Solomon SR, Sizemore CA, Sanacore M, Zhang X, Brown S, Holland HK, Morris LE, Bashey A. Total Body Irradiation-Based Myeloablative Haploidentical Stem Cell Transplantation Is a Safe and Effective Alternative to Unrelated Donor Transplantation in Patients Without Matched Sibling Donors. Biol Blood Marrow Transplant. 2015 Jul;21(7):1299-307. doi: 10.1016/j.bbmt.2015.03.003. Epub 2015 Mar 19. PubMed 25797174 ↗
  • Solomon SR, Sizemore CA, Sanacore M, Zhang X, Brown S, Holland HK, Morris LE, Bashey A. Haploidentical transplantation using T cell replete peripheral blood stem cells and myeloablative conditioning in patients with high-risk hematologic malignancies who lack conventional donors is well tolerated and produces excellent relapse-free survival: results of a prospective phase II trial. Biol Blood Marrow Transplant. 2012 Dec;18(12):1859-66. doi: 10.1016/j.bbmt.2012.06.019. Epub 2012 Aug 1. PubMed 22863841 ↗
  • O'Donnell PV, Luznik L, Jones RJ, Vogelsang GB, Leffell MS, Phelps M, Rhubart P, Cowan K, Piantados S, Fuchs EJ. Nonmyeloablative bone marrow transplantation from partially HLA-mismatched related donors using posttransplantation cyclophosphamide. Biol Blood Marrow Transplant. 2002;8(7):377-86. doi: 10.1053/bbmt.2002.v8.pm12171484. PubMed 12171484 ↗
  • Luznik L, Engstrom LW, Iannone R, Fuchs EJ. Posttransplantation cyclophosphamide facilitates engraftment of major histocompatibility complex-identical allogeneic marrow in mice conditioned with low-dose total body irradiation. Biol Blood Marrow Transplant. 2002;8(3):131-8. doi: 10.1053/bbmt.2002.v8.pm11939602. PubMed 11939602 ↗
  • Luznik L, Jalla S, Engstrom LW, Iannone R, Fuchs EJ. Durable engraftment of major histocompatibility complex-incompatible cells after nonmyeloablative conditioning with fludarabine, low-dose total body irradiation, and posttransplantation cyclophosphamide. Blood. 2001 Dec 1;98(12):3456-64. doi: 10.1182/blood.v98.12.3456. PubMed 11719388 ↗
  • Eto M, Mayumi H, Tomita Y, Yoshikai Y, Nishimura Y, Maeda T, Ando T, Nomoto K. Specific destruction of host-reactive mature T cells of donor origin prevents graft-versus-host disease in cyclophosphamide-induced tolerant mice. J Immunol. 1991 Mar 1;146(5):1402-9. PubMed 1671578 ↗
  • Matsuura A, Katsuno M, Suzuki Y, Ito T, Yasuura K, Abe T, Yoshikai Y. Cyclophosphamide-induced tolerance in fully allogeneic heart transplantation in mice. Cell Immunol. 1994 May;155(2):501-7. doi: 10.1006/cimm.1994.1142. PubMed 8181080 ↗
  • Eto M, Mayumi H, Tomita Y, Yoshikai Y, Nishimura Y, Nomoto K. Sequential mechanisms of cyclophosphamide-induced skin allograft tolerance including the intrathymic clonal deletion followed by late breakdown of the clonal deletion. J Immunol. 1990 Sep 1;145(5):1303-10. PubMed 2143514 ↗
  • Mayumi H, Umesue M, Nomoto K. Cyclophosphamide-induced immunological tolerance: an overview. Immunobiology. 1996 Jul;195(2):129-39. doi: 10.1016/S0171-2985(96)80033-7. PubMed 8877390 ↗
  • Nirmul G, Severin C, Taub RN. Mechanisms and kinetics of cyclophosphamide-induced specific tolerance to skin allografts in mice. Transplant Proc. 1973 Mar;5(1):675-8. No abstract available. PubMed 4572127 ↗
  • Nirmul G, Severin C, Taub RN. Cyclophosphamide-induced immunologic tolerance to skin homografts. Surg Forum. 1971;22:287-8. No abstract available. PubMed 4941317 ↗
  • BERENBAUM MC, BROWN IN. DOSE-RESPONSE RELATIONSHIPS FOR AGENTS INHIBITING THE IMMUNE RESPONSE. Immunology. 1964 Jan;7(1):65-71. PubMed 14113077 ↗
  • Strauss G, Osen W, Debatin KM. Induction of apoptosis and modulation of activation and effector function in T cells by immunosuppressive drugs. Clin Exp Immunol. 2002 May;128(2):255-66. doi: 10.1046/j.1365-2249.2002.01777.x. PubMed 11985515 ↗
  • Brodsky RA, Petri M, Smith BD, Seifter EJ, Spivak JL, Styler M, Dang CV, Brodsky I, Jones RJ. Immunoablative high-dose cyclophosphamide without stem-cell rescue for refractory, severe autoimmune disease. Ann Intern Med. 1998 Dec 15;129(12):1031-5. doi: 10.7326/0003-4819-129-12-199812150-00007. PubMed 9867758 ↗
  • Emadi A, Jones RJ, Brodsky RA. Cyclophosphamide and cancer: golden anniversary. Nat Rev Clin Oncol. 2009 Nov;6(11):638-47. doi: 10.1038/nrclinonc.2009.146. Epub 2009 Sep 29. PubMed 19786984 ↗
  • Whirl-Carrillo M, McDonagh EM, Hebert JM, Gong L, Sangkuhl K, Thorn CF, Altman RB, Klein TE. Pharmacogenomics knowledge for personalized medicine. Clin Pharmacol Ther. 2012 Oct;92(4):414-7. doi: 10.1038/clpt.2012.96. PubMed 22992668 ↗
  • Anasetti C, Amos D, Beatty PG, Appelbaum FR, Bensinger W, Buckner CD, Clift R, Doney K, Martin PJ, Mickelson E, et al. Effect of HLA compatibility on engraftment of bone marrow transplants in patients with leukemia or lymphoma. N Engl J Med. 1989 Jan 26;320(4):197-204. doi: 10.1056/NEJM198901263200401. PubMed 2643045 ↗
  • Beatty PG, Clift RA, Mickelson EM, Nisperos BB, Flournoy N, Martin PJ, Sanders JE, Stewart P, Buckner CD, Storb R, et al. Marrow transplantation from related donors other than HLA-identical siblings. N Engl J Med. 1985 Sep 26;313(13):765-71. doi: 10.1056/NEJM198509263131301. PubMed 3897863 ↗
  • Powles RL, Morgenstern GR, Kay HE, McElwain TJ, Clink HM, Dady PJ, Barrett A, Jameson B, Depledge MH, Watson JG, Sloane J, Leigh M, Lumley H, Hedley D, Lawler SD, Filshie J, Robinson B. Mismatched family donors for bone-marrow transplantation as treatment for acute leukaemia. Lancet. 1983 Mar 19;1(8325):612-5. doi: 10.1016/s0140-6736(83)91793-2. PubMed 6131300 ↗

Individual participant data

Plan to share: No — At this time, we do not plan to share individual participant data (IPD) due to concerns regarding patient privacy, the regulatory requirements for data sharing for maintaining patient confidentiality

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Mar 2025 (actual). Primary completion is estimated for Nov 2028, 43 months after the start.

Of 114 non-industry phase 2 interventional studies under Hematologic Neoplasms, half reached primary completion within 59 months of starting (the median), counting those still running; a quarter within 42 and three quarters within 95. This study's planned 43 months is below that.

Counting every sponsor, half of 136 studies reached it within 57 months; a quarter within 40 and three quarters within 94.

How these figures are worked out, and which studies are left out of them.

Registered
Jul 10, 2026
First posted
Jul 22, 2026
StartActual
Mar 26, 2025
Primary completionEst.
Nov 12, 2028
CompletionEst.
Nov 12, 2028
Last update
Jul 22, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jul 22, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07719946
Lead sponsor
Tata Memorial Centre
Collaborators
Indian Council of Medical Research
Responsible party
Dr Sachin Punatar (Professor & Medical Oncologist, Tata Memorial Centre) — Principal investigator
First posted
Jul 22, 2026
Start date
Mar 26, 2025
Primary completion
Nov 12, 2028 (estimated)
Completion
Nov 12, 2028 (estimated)
Last update
Jul 22, 2026

Study contacts

Dr Sachin Punatar, MBBS MD DM medical oncology
Contact
drsachin_punatar@yahoo.in
09833445041
Dr.Akanksha Chichra, FNB,,DNB Pediatric oncology
Contact
akanksha7@hotmail.com

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Cyclophosphamide

Start the discussion